Investigators will be presenting exciting data on several treatments for multiple myeloma at the American Society of Hematology (ASH) meeting, noted Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.
Investigators will be presenting exciting data on several treatments for multiple myeloma at the American Society of Hematology (ASH) meeting, noted Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.
Transcript
What will be the biggest takeaways from this year’s ASH meeting?
I’m very focused on the on the myeloma sessions today. And I think on the Janssen side, right, we’ve been innovating in the myeloma space for the last 15 years. We have 4 different compounds in the multiple myeloma space being reported on at ASH. We have daratumumab, we have our CAR T cilta-cel, or JNJ-4528. We’re extremely excited to be presenting the first results from our bispecific antibody called talquetamab, which targets GPRC5D. And as a T-cell redirector, these are the first results from that phase 1 study. And then we also reporting updated data from a similar phase 1 study with teclistamab, which is our BCMAxCD3 for multiple myeloma.
You need to build regimens to really advance care for patients. Teclistamab, talquetamab, cilta-cel, daratumumab, we believe that these are all important components to build regimens to get patients towards the ultimate goal of hopefully trying to eradicate disease and get meaningful cure. We’re excited about talquetamab. We’ve reached a recommended phase 2 dose; it seems to be highly efficacious in patients who are triple refractory and run out of options; similarly, teclistamab; similarly, cilta-cel.
So for me, I’m really excited to see the reaction of the medical community about the multiple myeloma data that we’re bringing forward, and we’re already seeing excitement from that. We saw Vincent Rajkumar [S. Vincent Rajkumar, MD, Mayo Clinic] already tweeting out that the talquetamab abstract is his No. 1 favorite for ASH. So tip my hat to Vincent Rajkumar with that. We’re excited about it, too, and I think that we’re on the cusp of continuing to look toward bringing forward new therapies that can really advance care for patients.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More